key: cord-1006315-xd79f4sh
authors: Huggins, David J.
title: Structural Analysis of Experimental Drugs Binding to the SARS-CoV-2 Target TMPRSS2
date: 2020-08-11
journal: J Mol Graph Model
DOI: 10.1016/j.jmgm.2020.107710
sha: ad3ace03ae3ea946b210b25d1073e5c3dd4693b6
doc_id: 1006315
cord_uid: xd79f4sh

The emergence of SARS-CoV-2 has prompted a worldwide health emergency. There is an urgent need for therapeutics, both through the repurposing of approved drugs and the development of new treatments. In addition to the viral drug targets, a number of human drug targets have been suggested. In theory, targeting human proteins should provide an advantage over targeting viral proteins in terms of drug resistance, which is commonly a problem in treating RNA viruses. This paper focuses on the human protein TMPRSS2, which supports coronavirus life cycles by cleaving viral spike proteins. The three-dimensional structure of TMPRSS2 is not known and so we have generated models of the TMPRSS2 in the apo state as well as in complex with a peptide substrate and putative inhibitors to aid future work. Importantly, many related human proteases have 80% or higher identity with TMPRSS2 in the S1-S1’ subsites, with plasminogen and urokinase-type plasminogen activator (uPA) having 95% identity. We highlight 376 approved, investigational or experimental drugs targeting S1A serine proteases that may also inhibit TMPRSS2. Whilst the presence of a relatively uncommon lysine residue in the S2/S3 subsites means that some serine protease inhibitors will not inhibit TMPRSS2, this residue is likely to provide a handle for selective targeting in a focused drug discovery project. We discuss how experimental drugs targeting related serine proteases might be repurposed as TMPRSS2 inhibitors to treat coronaviruses.

paper focuses on the human protein TMPRSS2, which supports coronavirus life cycles by 18 cleaving viral spike proteins. The three-dimensional structure of TMPRSS2 is not known and so 19

we have generated models of the TMPRSS2 in the apo state as well as in complex with a peptide 20 substrate and putative inhibitors to aid future work. Importantly, many related human proteases 21 have 80% or higher identity with TMPRSS2 in the S1-S1' subsites, with plasminogen and 22 urokinase-type plasminogen activator (uPA) having 95% identity. We highlight 376 approved, 23 investigational or experimental drugs targeting S1A serine proteases that may also inhibit 24 TMPRSS2. Whilst the presence of a relatively uncommon lysine residue in the S2/S3 subsites 25 means that some serine protease inhibitors will not inhibit TMPRSS2, this residue is likely to 26 provide a handle for selective targeting in a focused drug discovery project. We discuss how 27 experimental drugs targeting related serine proteases might be repurposed as TMPRSS2 28 inhibitors to treat coronaviruses. 29

There is an urgent need to identify drugs and drug targets which are effective in treating COVID-36 19 . Numerous drug targets have been suggested (1) and a plethora of drug repurposing efforts are 37 underway. (2,3) Transmembrane Serine Protease 2 (TMPRSS2) is a membrane bound serine 38 protease also known as Epitheliasin. TMPRSS2 belongs to the S1A class of serine proteases 39 alongside proteins such as factor Xa and trypsin. Whilst there is evidence that TMPRSS2 40 autocleaves to generate a secreted protease,(4) its physiological function has not been clearly 41 identified, However, it is known to play a crucial role in facilitating entry of coronavirus 42 particles into cells by cleaving the spike protein.(5,6) Coronavirus spike proteins are thought to 43 be cleaved at two sites, termed S1/S2 and S2'.(7-9) The proteases furin, trypsin, cathepsin, 44 TMPRSS2, TMPRSS4, TMPRSS11, and human airway trypsin-like protease have all been 45 implicated in these cleavages.(9-13) For SARS-CoV, the S2' cleavage site has a sequence motif 46 (PTKR|S) that appears suitable for cleavage by trypsin-like proteases such as TMPRSS2 whereas 47 drug target for coronaviruses (18, 19) such as SARS-CoV-2. (20) TMPRSS2 is highly expressed 59 in lung tissue (21) and it has been suggested that differential expression in males may lead to 60 higher risk in male patients. (22) We selected a subset of sequences for alignment based on availability of structural data and 80 similarity between sequences in the active site. We looked in particular at the identity in the 81 active site of the enzymes to inform model and compound selection. We identified 20 residues 82 close to the active site (S1-S1') as well as a larger set of 34 residues spanning the whole binding 83 site (S4-S3-S2-S1-S1'-S2'-S3'-S4'). These residues are identified in Figure 1 . The percentage 84 identities between TMPRSS2 and this subset are given in Table 1 Table 1 -A subset of human S1A serine proteases and the percentage identity with TMPRSS2 of 88 their protease domains, S1-S1' subsites, and S4-S3-S2-S1-S1'-S2'-S3'-S4' subsites. 89

Importantly, many of the proteases have 80% or higher identity with TMPRSS2 in the S1-S1' 91 subsites, with plasminogen and urokinase-type plasminogen activator (uPA) having 95% 92 identity. We selected the protein TMPRSS15 to generate a homology model (also known as 93 enteropeptidase). TMPRSS15 provides a good template for building a homology model of 94 TMPRSS2, with a deletion of two residues and an insertion of one residue. It also features a 95 lysine residue in the S2/S3 subsites, which is unique to TMPRSS2 and TMPRSS15. The 96 alignment of the TMPRSS2 and TMPRSS15 protease domains is shown in Figure 1 . TMPRSS15. The loop regions that were remodelled are highlighted by green bars. TMPRSS2 100 residues in the S4-S3-S2-S1-S1'-S2'-S3'-S4' subsites are colored red. TMPRSS2 residues in the 101 S1-S1' subsites are further highlighted in bold. The lysine residue between the S2/S3 subsites is 102 highlighted with a blue arrow. 103

Selenomethionines were changed to methionines and missing side-chains were added using 106

Schrödinger's Preparation Wizard, which was also used to evaluate the orientations of the 107 asparagine, glutamine, and histidine residues, as well as the protonation state of all ionizable 108 residues. All heteroatomic species such as buffer solvents and ions were removed. Water 109 molecules in the arginine binding site were retained. The TMPRSS2 loop sequences 110 EKPLNNPWH, QSFMSY, and VYDNLITPA (see Figure 1 ) were remodelled using 111

Schrodinger's Prime and the whole protein was then energy minimized with the heavy atoms 112 converged to an RMSD of 0.3 Angstroms. The homology model of TMPRS22 is available on 113

Github overlaid with the benzamidine molecule from PDBID 2OQ5 (28): 114 https://github.com/djhuggins/TMPRSS2/blob/master/HomologyModels/TMPRSS2_HomologyM 115 odel_Enteropeptidase4DGJ_BenzamidineOverlay.pdb 116

To assess the quality of the homology model, we performed 100 ns of molecular dynamics using 117 the Desmond package. The system was set up as an orthorhombic box with a minimum distance 118 of 10 Angstroms from the protein to the box edge. Water was modelled with the SPC water 119 model and the OPLS3e forcefield was used for the protein and ligand. 100 ns of simulation was 120 then performed in the NPT ensemble at 300 K and 1.01325 bar. Figure 2 shows the RMSD of the 121 protein and the ligand during the simulation. Both stabilize within the first 10 ns. The protein 122 remains stable, with an alpha carbon RMSD around 1.7 Angstroms relative to the original 123 structure and always below 2.0 Angstroms. The ligand also remains stable, with an RMSD 124 around 0.9 Angstroms relative to the original structure and always below 2.5 Angstroms. 125 Ångström of the S1-S1' sites are displayed as red space filling. Residues within 4 Ångström of 141 the S4-S3-S2-S1-S1'-S2'-S3'-S4' sites are displayed as orange sticks. Based on the homology model described above, the S2-S3 subsites of TMPRSS2 appear to be 181 different than that of related proteases due to the presence of a charge residue Lys392 (see Figure  182 3). Whilst this suggests that many existing serine protease inhibitors which fill these subsites will 183 not bind to TMPRSS2, it presents an opportunity to develop selective inhibitors in the future to 184 exploit TMPRSS2 selectively in therapeutic settings. Figure 4 presents the predicted TMPRSS2 185 binding modes for a set of non-covalent S1A serine protease experimental drugs overlaid with 186 the experimental crystal structures of the drugs bound to their known target. These drugs target 187 the S1-S1' subsites where identity between the S1A serine proteases is very high (see Table 2 ). The S1-S1' subsites of TMPRSS2 has a high similarity to the known targets of all these drugs 205 (see Table 1 ). Table 3 -A set of experimental drugs targeting S1A serine proteases that may inhibit TMPRSS2 210 and are modelled in Figure 3 . Camostat targets furin in addition to S1A proteases given a mechanism of action where it 235 covalently binds to the arginine binding site. However, at this stage there is significantly more 236 evidence that targeting TMPRSS2 will effectively treat SARS-CoV-2. The known TMPRSS2 237 inhibitor Camostat is being assessed in a clinical trial against COVID-19 and other inhibitors, 238 such as Namafostat, look to be effective in cell-based studies. However, it seems highly likely 239 that these simple covalent binders may inhibit other S1A serine proteases and this may lead to 240 unwanted side effects for these drugs. TMPRSS2 knockout mice develop normally with no observable phenotype suggesting that it may be safely targeted.(46) To maximize safety, it 242 would be very useful to identify exactly which proteases are key to cleaving the SARS-CoV-2 243 spike protein. Recent work suggests that TMPRSS2 and TMPRSS4 may both be important. (47) 244 This work identifies a number of experimental drugs for serine proteases that may effectively 245 inhibit TMPRSS2 based on homology and Embrace binding free energy calculations. Three are 246 shown in Table 4 . 

Therapeutic options for the 2019 novel coronavirus

Fast Identification of Possible Drug Treatment of Coronavirus Disease-19

COVID-19) through Computational Drug Repurposing Study

Network-based drug repurposing 277 for novel coronavirus 2019-nCoV/SARS-CoV-2

Catalytic cleavage of the 280 androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate 281 cancer epithelia

CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven 284

The spike 311 glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in

CoV of the same clade

Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct

Proteolytically Sensitive Activation Loop

Protease Cleavage Site 318 Predicted in the Spike Protein of the Novel Pneumonia Coronavirus

Potentially Related to Viral Transmissibility

TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine 323 Models after Coronavirus Infection

TMPRSS2: A potential target for

Interaction with the S1β-pocket of urokinase: 8-heterocycle substituted and 6,8-374 disubstituted 2-naphthamidine urokinase inhibitors

Bioorganic & 375 Medicinal Chemistry Letters

Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of 379 urokinase-type plasminogen activator

Novel 5-381 azaindole factor VIIa inhibitors

Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of 384 human urokinase

Proceedings of the National Academy of Sciences

inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug 395 targets

Coronaviruses -drug discovery and 397 therapeutic options

New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, 400 kallikrein and trypsin

Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-403

Quantitative metrics for drug-target ligandability. Drug Discov 406 Today

CoV-2 infection of human small intestinal enterocytes. bioRxiv [Internet